|
1) Bao AM, Meynen G, Swaab DF. The stress system in depression and neurodegeneration: Focus on the human hypothalamus. Brain Res Rev. 2007 Apr 27; [Epub ahead of print]
|
|
|
|
|
2) Swaab DF, Bao AM, Lucassen PJ. The stress system in the human brain in depression and neurodegeneration. Ageing Res Rev. 2005; 4: 141-94
|
|
|
|
|
3) Raadsheer FC, Hoogendijk WJ, Stam FC, et al. Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology. 1994; 60: 436-44
|
|
|
|
|
|
4) Raadsheer FC, van Heerikhuize JJ, Lucassen PJ, et al. Corticotropin-releasing hormone mRNA levels in the paraventricular nucleus of patients with Alzheimer's disease and depression. Am J Psychiatry. 1995; 152: 1372-6
|
|
|
|
|
|
5) Dinan TG, Lavelle E, Cooney J, et al. Dexamethasone augmentation in treatment-resistant depression. Acta Psychiatr Scand. 1997; 95: 58-61
|
|
|
|
|
|
6) Holsboer F. Stress, hypercortisolism and corticosteroid receptors in depression: implications for therapy. J Affect Disord. 2001; 62: 77-91
|
|
|
|
|
|
7) Liu Z, Zhu F, Wang G, et al. Association of corticotropinreleasing hormone receptor1 gene SNP and haplotype with major depression. Neurosci Lett. 2006; 404: 358-62
|
|
|
|
|
|
8) Scott LV, Dinan TG. Vasopressin and the regulation of hypothalamic-pituitary-adrenal axis function: implications for the pathophysiology of depression. Life Sci. 1998; 62: 1985-98
|
|
|
|
|
|
9) van Londen L, Goekoop JG, van Kempen GM, et al. Plasma levels of arginine vasopressin elevated in patients with major depression. Neuropsychopharmacology. 1997; 17: 284-92
|
|
|
|
|
|
10) Meynen G, Unmehopa UA, van Heerikhuize JJ, et al. Increased arginine vasopressin mRNA expression in the human hypothalamus in depression: A preliminary report. Biol Psychiatry. 2006; 60: 892-5
|
|
|
|
|
|
11) Inder WJ, Donald RA, Prickett TC, et al. Arginine vasopressin is associated with hypercortisolemia and suicide attempts in depression. Biol Psychiatry. 1997; 42: 744-7
|
|
|
|
|
|
12) Mlynarik M, Zelena D, Bagdy G, et al. Signs of attenuated depression-like behavior in vasopressin deficient Brattleboro rats. Horm Behav. 2007; 51: 395-405
|
|
|
|
|
|
13) van Londen L, Goekoop JG, Kerkhof GA, et al. Weak 24-h periodicity of body temperature and increased plasma vasopressin in melancholic depression. Eur Neuropsychopharmacol. 2001; 11: 7-14
|
|
|
|
|
|
14) Johansson C, Willeit M, Smedh C, et al. Circadian clock-related polymorphisms in seasonal affective disorder and their relevance to diurnal preference. Neuropsychopharmacology. 2003; 28: 734-9
|
|
|
|
|
|
15) Liu RY, Unmehopa UA, Zhou JN, et al. Glucocorticoids suppress vasopressin gene expression in human suprachiasmatic nucleus. J Steroid Biochem Mol Biol. 2006; 98: 248-53
|
|
|
|
|
|
16) Wirz-Justice A, Benedetti F, Berger M, et al. Chronotherapeutics (light and wake therapy) in affective disorders. Psychol Med. 2005; 35: 939-44
|
|
|
|
|
|
17) Kalsbeek A, Buijs RM, van Heerikhuize JJ, et al. Vasopressin-containing neurons of the suprachiasmatic nuclei inhibit corticosterone release. Brain Res. 1992; 580: 62-7
|
|
|
|
|
|
18) van West D, Van Den Eede F, Del-Favero J, et al. Glucocorticoid receptor gene-based SNP analysis in patients with recurrent major depression. Neuropsychopharmacology. 2006; 31: 620-7
|
|
|
|
|
|
19) Reus VI, Wolkowitz OM, Frederick S. Antiglucocorticoid treatments in psychiatry. Psychoneuroendocrinology. 1997; 22 Suppl 1: S121-4
|
|
|
|
|
|
20) Murphy BE. Antiglucocorticoidtherapies in major depression: a review. Psychoneuroendocrinology. 1997; 22 Suppl 1: S125-32
|
|
|
|
|
|
21) Gold PW, Drevets WC, Charney DS. New insights into the role of cortisol and the glucocorticoid receptor in severe depression. Biol Psychiatry. 2002; 52: 381-5
|
|
|
|
|
|
22) Belanoff JK, Rothschild AJ, Cassidy F, et al. An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry. 2002; 52: 386-92
|
|
|
|
|
|
23) Gold PW, Chrousos GP. Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. Mol Psychiatry. 2002; 7: 254-75
|
|
|
|
|
|
24) Pfennig A, Kunzel HE, Kern N, et al. Hypothalamus-pituitary-adrenal system regulation and suicidal behavior in depression. Biol Psychiatry. 2005; 57: 336-42
|
|
|
|
|
|
25) Steimer T, Python A, Schulz PE, et al. Plasma corticosterone, dexamethasone (DEX) suppression and DEX/CRH tests in a rat model of genetic vulnerability to depression. Psychoneuroendocrinology. 2007; 32: 575-9
|
|
|
|
|
|
26) Mann JJ, Currier D. A review of prospective studies of biologic predictors of suicidal behavior in mood disorders. Arch Suicide Res. 2007; 11: 3-16
|
|
|
|
|